Before analyzing IFITM3 expression in hepatocellular carcinoma patients, we noted the distinguishing factors for the patients as listed in Table 1 the age of the cancer patients ranged from 40 to 75 years, the proportion was male (78%) and female (22%), and the patients with cancer had a family history (52%). The gene discussed is IFITM3; the disease is hepatocellular carcinoma.